Omalizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Omalizumab and local guidelines before prescribing.
Anti-IgE monoclonal antibody
Mechanism
Anti-IgE monoclonal antibody.
Uses
Severe allergic asthma, chronic spontaneous urticaria, nasal polyps.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reactions, anaphylaxis (rare), headache.
Interactions
Few.
Contraindications and cautions
Anaphylaxis history
Monitoring
Asthma control
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Observe after injection; check total IgE and weight for dosing.
More from the textbook: uses, cautions and other points
- Risks - injection reactions, rare anaphylaxis (omalizumab), parasitic infections (anti-eosinophil drugs - screen travellers).
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab | IgE | Severe allergic asthma (raised IgE, sensitised to perennial allergens); also chronic urticaria
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab / mepolizumab / benralizumab / dupilumab / tezepelumab | Biologics for severe asthma (specialist).
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab (anti-IgE): Severe allergic asthma with raised IgE.
Respiratory: Airways Disease - Biologics (omalizumab, anti-IL-5) in difficult cases.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - Chronic spontaneous urticaria not responding - refer: omalizumab (anti-IgE, NICE TA339), then ciclosporin; montelukast in some.
Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies - Steroid-sparing - azathioprine, methotrexate, mycophenolate; dupilumab or omalizumab in resistant cases.
Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (3 mentions)
- Respiratory: Airways Disease (3 mentions)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (5 mentions)
- Clinical Immunology: Allergy, anaphylaxis, urticaria and angioedema (6 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (3 mentions)